Market research
600535.SHG Tasly Pharmaceutical Group Co., Ltd
SHG CNY Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 21B
- P/E ratio
- 16.8
- Analyst target
- 17.29
- Dividend yield
- 0.7%
- Beta
- 0.21
Profile
Instrument facts
- Exchange
- SHG
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CNE000001C81
- Market cap
- 21B
- P/E ratio
- 16.8
- Analyst target
- 17.29
- Dividend yield
- 0.7%
- Beta
- 0.21
About
About Tasly Pharmaceutical Group Co., Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical drugs. It also engages in medical instruments, agriculture, and chain drugstore activities. The company was formerly known as Tianjin Tasly Pharmaceutical Co., Ltd. and changed its name to Tasly Pharmaceutical Group Co., Ltd in May 2012. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China.
Research context
Tasly Pharmaceutical Group Co., Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 600535.SHG discussion.
5 years, 6 months ago
Tasly Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 4.8% below its 200 day moving average.
From a valuation standpoint, the stock is 87.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.2.
Tasly Pharmaceutical Group Co., Ltd's total revenue sank by 40.8% to $3B since the same quarter in the previous year.
Its net income has increased by 77.3% to $414M since the same quarter in the previous year.
Finally, its free cash flow fell by 213.5% to $-267M since the same quarter in the previous year.
Based on the above factors, Tasly Pharmaceutical Group Co., Ltd gets an overall score of 2/5.